ArticleAnnals of translational medicine2016
αvβ1 integrin as a novel therapeutic target for tissue fibrosis.
Article in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- αvβ3 Integrin as a Link between the Development of Fibrosis and Thyroid Hormones in Systemic Sclerosis.International journal of molecular sciences · 2023Article
- Soluble ITGaM and ITGb2 Integrin Subunits Are Involved in Long-Term Pulmonary Complications after COVID-19 Infection.Journal of clinical medicine · 2023Article
- Short-term tetrabromobisphenol A exposure promotes fibrosis of human uterine fibroid cells in a 3D culture system through TGF-beta signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Cooperative signaling between integrins and growth factor receptors in fibrosis.Journal of molecular medicine (Berlin, Germany) · 2021Review
- TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation.Cancer science · 2020Article
- Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.Nature reviews. Rheumatology · 2020Review
- The role of TGF-beta signaling in dendritic cell tolerance.Immunologic research · 2017Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic tissue injury with fibrosis results in disruption of tissue architecture, organ dysfunction and eventually organ failure. Currently, therapeutic options for tissue fibrosis are severely limited and organ transplantation including high cost and co-morbidities is the only effective treatment for end-stage fibrotic disease. Therefore, it is imperative to develop effective anti-fibrotic agents. Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis. In this perspective, we reviewed the functions of αvβ1 integrin as a potentially useful target molecule for antifibrotic agent and introduced novel specific small-molecule inhibitors targeting this integrin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.